Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL10036575 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL1200511 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3398599 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL29355040 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211911-A1 | METHODS FOR TREATING DEPRESSIVE STATES | OAKTREE FUND ADMINISTRATION, LLC (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4363057-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117750956-A | Methods for treating depressive states | 比奥克斯塞尔医疗股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023278824-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BIOXCEL THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |